Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity

OBJECTIVES: We assessed humoral responses and reactogenicity following the heterologous vaccination compared to the homologous vaccination groups. METHODS: We enrolled healthcare workers (HCWs) who were either vaccinated with ChAdOx1 followed by BNT162b2 (heterologous group) or 2 doses of ChAdOx1 (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Seongman, Ko, Jae-Hoon, Choi, Ju-Yeon, Park, Woo-Jung, Lim, So Yun, Ahn, Jin Young, Song, Kyoung-Ho, Lee, Kyoung Hwa, Song, Young Goo, Chan Kim, Yong, Park, Yoon Soo, Choi, Won Suk, Jeong, Hye Won, Kim, Shin-Woo, Kwon, Ki Tae, Kang, Eun-Suk, Kim, Ah-Ra, Jang, Sundong, Kim, Byoungguk, Kim, Sung Soon, Jang, Hee-Chang, Choi, Jun Yong, Kim, Sung-Han, Peck, Kyong Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117169/
https://www.ncbi.nlm.nih.gov/pubmed/35598855
http://dx.doi.org/10.1016/j.cmi.2022.04.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117169/
https://www.ncbi.nlm.nih.gov/pubmed/35598855
http://dx.doi.org/10.1016/j.cmi.2022.04.019

Ejemplares similares